CLINICAL TRIAL: INTERVENTIONS TO IMPROVE MEMORY IN PATIENTS WITH MULTIPLE SCLERO

临床试验：改善多发性硬化症患者记忆力的干预措施

• 批准号: 7950797
• 负责人: LAUREN B KRUPP
• 金额: $ 0.66万
• 依托单位: STATE UNIVERSITY NEW YORK STONY BROOK
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7950797
• 关键词: Affect; Alzheimer' s Disease; Aricept; Attention; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Disease; Effectiveness; FDA approved; Funding; Grant; Impaired cognition; Institution; Intervention; Learning; Memory; Patients; Research; Research Personnel; Resources; Source; Testing; United States National Institutes of Health; Work; donepezil; experience; improved; social

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. MS is a disease that is frequently associated with cognitive impairment. Cognitive impairment can affect somebody's ability to work and engage in social activities. Over 60% of MS patients experience some cognitive impairment. Donepezil (Aricept) is being investigated as a possible treatment for MS related cognitive impairment. We will test the effectiveness of donepezil in improving memory and attention in MS. Donepezil is currently FDA approved for improving learning and memory in patients with Alzheimer's disease but not with MS.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 MS是一种经常与认知障碍相关的疾病。认知障碍会影响一个人的工作能力和参与社会活动的能力。超过60%的MS患者经历一些认知障碍。 正在研究多奈哌齐（安理申）作为MS相关认知障碍的可能治疗方法。我们将测试多奈哌齐在改善MS的记忆和注意力方面的有效性。多奈哌齐目前已被FDA批准用于改善阿尔茨海默病患者的学习和记忆，但未被批准用于MS。